Vanguard Personalized Indexing Management LLC Sells 3,499 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Vanguard Personalized Indexing Management LLC has reduced its stake in Zimmer Biomet Holdings, Inc. by 22.3%, selling 3,499 shares in the second quarter, leaving them with 12,194 shares valued at approximately $1,113,000.
• Zimmer Biomet reported quarterly earnings of $2.07 per share, exceeding analysts' expectations of $1.98, with revenues of $2.08 billion, reflecting a 7% increase from the previous year.
• The company has announced a dividend of $0.24 per share, with a scheduled payment date of October 31, and a dividend yield of 0.9%.

Vanguard Personalized Indexing Management LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 22.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,194 shares of the medical equipment provider's stock after selling 3,499 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Zimmer Biomet were worth $1,113,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZBH. Garde Capital Inc. bought a new position in shares of Zimmer Biomet in the 1st quarter valued at about $29,000. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet during the first quarter worth $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet during the first quarter worth $30,000. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet in the 1st quarter valued at about $35,000. Finally, Cullen Frost Bankers Inc. grew its holdings in Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 305 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 2.1%

ZBH stock opened at $102.00 on Friday. The firm has a 50-day moving average price of $101.74 and a 200-day moving average price of $97.78. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $20.21 billion, a P/E ratio of 24.82, a price-to-earnings-growth ratio of 2.35 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company's stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.39% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. BTIG Research increased their price target on Zimmer Biomet from $118.00 to $122.00 and gave the company a "buy" rating in a research note on Monday, October 13th. UBS Group boosted their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research report on Friday, August 8th. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research report on Thursday, September 18th. Finally, Evercore ISI lowered their price objective on Zimmer Biomet from $106.00 to $104.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus target price of $111.94.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.